Skip to main content

Advertisement

Table 3 Hair re-growth on dogs with generalized demodectic mange after treatment with Bravectoor Advocate®

From: Efficacy of orally administered fluralaner (BravectoTM) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs

Study day Estimated percent hair re-growth a
Bravecto ™b (number of dogs/number of dogs per group) Advocate® c (number of dogs/number of dogs per group)
0-50% 50-90% >90% 0-50% 50-90% >90%
28 3/8 1/8 4/8 6/8 1/8 1/8
56 0/8 1/8 7/8 0/8 1/8 7/8
84 0/8 1/8 7/8 0/7d 1/7d 6/7d
  1. aPercentage hair re-growth defined as estimated percentage of hair cover growth compared to baseline total hairless area as assessed prior to veterinary product administration.
  2. bDogs were treated once orally on Day 0.
  3. cDogs were treated topically on Day 0, on Day 28 and again on Day 56. Hair assessments were performed before treatment.
  4. dOn day 59 one dog had to be euthanized due to the presence of a malign tumour in the stomach.